Saveanu L, Daniel S, van Endert P M
INSERM U25, 161 rue de Sèvres, 75743 Paris cedex 15, France.
J Biol Chem. 2001 Jun 22;276(25):22107-13. doi: 10.1074/jbc.M011221200. Epub 2001 Apr 4.
The transporters associated with antigen processing (TAP1/TAP2) provide peptides to MHC class I molecules in the endoplasmic reticulum. Like other ATP-binding cassette proteins, TAP uses ATP hydrolysis to power transport. We have studied peptide binding to as well as translocation by TAP proteins with mutations in the Walker A and B sequences that are known to mediate ATP binding and hydrolysis. We show that a mutation in the TAP1 Walker B sequence reported to abrogate class I expression by a lung tumor does not affect ATP binding affinity, suggesting a defect restricted to ATP hydrolysis. This mutation reduces peptide transport by only 50%, suggesting that TAP function can be highly limiting for antigen presentation in non-lymphoid cells. Single substitutions in Walker A sequences (TAP1K544A, TAP2K509A), or their complete replacements, abrogate nucleotide binding to each subunit. Although all of these mutations abrogate peptide transport, they reveal distinct roles for nucleotide binding to the two transporter subunits in TAP folding and in regulation of peptide substrate affinity, respectively. Alteration of the TAP1 Walker A motif can have strong effects on TAP1 and thereby TAP complex folding. However, TAP1 Walker A mutations compatible with correct folding do not affect peptide binding. In contrast, abrogation of the TAP2 nucleotide binding capacity has little or no effect on TAP folding but eliminates peptide binding to TAP at 37 degrees C in the presence of nucleotides. Thus, nucleotide binding to TAP2 but not to TAP1 is a prerequisite for peptide binding to TAP. Based on these results, we propose a model in which nucleotide and peptide release from TAP are coupled and followed by ATP binding to TAP2, which induces high peptide affinity and initiates the transport cycle.
与抗原加工相关的转运体(TAP1/TAP2)在内质网中为MHC I类分子提供肽段。与其他ATP结合盒蛋白一样,TAP利用ATP水解来驱动转运。我们研究了肽段与TAP蛋白的结合以及TAP蛋白的转运情况,这些TAP蛋白在已知介导ATP结合和水解的沃克A和沃克B序列中存在突变。我们发现,据报道一个肺肿瘤中TAP1沃克B序列的突变可消除I类分子的表达,但该突变并不影响ATP结合亲和力,这表明缺陷仅限于ATP水解。此突变仅使肽段转运减少50%,这表明TAP功能在非淋巴细胞的抗原呈递中可能是高度受限的。沃克A序列中的单个取代(TAP1K544A、TAP2K509A)或其完全替换,会消除核苷酸与每个亚基的结合。尽管所有这些突变都消除了肽段转运,但它们分别揭示了核苷酸与两个转运亚基结合在TAP折叠以及肽段底物亲和力调节中的不同作用。TAP1沃克A基序的改变可对TAP1进而对TAP复合物折叠产生强烈影响。然而,与正确折叠兼容的TAP1沃克A突变并不影响肽段结合。相反,TAP2核苷酸结合能力的消除对TAP折叠几乎没有影响,但在有核苷酸存在的情况下,在37℃时会消除肽段与TAP的结合。因此,核苷酸与TAP2而非TAP1的结合是肽段与TAP结合的先决条件。基于这些结果,我们提出了一个模型,其中TAP释放核苷酸和肽段是偶联的,随后ATP与TAP2结合,这会诱导高肽段亲和力并启动转运循环。